Abstract
We have not added the abstract for this paper yet. The publisher's page has the full record.
Requiring an amyloid-beta 1-42 biomarker may improve the efficiency of a study, and simulations may help in planning studies
Alzheimer's Research & Therapy · Vol. 3 Published January 1, 2011
More on these topics
Browse all publications →-
2026 · Alzheimers Dement
Biomarkers in patients with clinical signs of mild cognitive impairment or mild Alzheimer's disease but without amyloid deposits on positron emission tomography: Results from Bio-Hermes Study participants
-
2026 · The Journal of Prevention of Alzheimer's Disease
Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer’s disease
-
2026 · J Prev Alzheimers Dis
A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer's disease
-
2025 · CNS Drugs
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer’s Disease: Synthesis of Evidence from Observational and Interventional Trials